StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report issued on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Down 3.4 %
Pulmatrix stock opened at $1.96 on Thursday. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $3.09. The stock has a market cap of $7.15 million, a P/E ratio of -0.51 and a beta of 0.90. The stock has a 50 day moving average of $1.88 and a 200-day moving average of $1.88.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%. The company had revenue of $2.20 million during the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- What is a Special Dividend?
- MarketBeat Week in Review – 4/29 – 5/3
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is the S&P/TSX Index?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
